44-week data bolster best-in-class case for Structure’s obesity pill

The latest Phase II data from Structure’s oral obesity therapy aleniglipron suggest it could be best in class, surpassing the weight loss reported for Novo Nordisk’s oral semaglutide and Eli Lilly’s small molecule orforglipron.

After reviving enthusiasm for aleniglipron with a Phase IIb readout in December, Structure Therapeutics Inc. (NASDAQ:GPCR) announced Monday longer-term data from its two Phase II trials of the oral GLP1-R agonist: the ACCESS II trial, which evaluated once-daily doses of 120 mg, 180 mg and 240 mg at 44 weeks, and the ACCESS open label extension study, which which titrated patients up to 120 mg at 56 weeks...